Top 3 Stocks Estimated To Be Undervalued On SEHK In July 2024

In This Article:

As global markets navigate through a myriad of economic signals, the Hong Kong market has shown particular resilience amidst regional uncertainties. In July 2024, investors are increasingly turning their attention to value stocks, which may present opportunities for those looking for potentially undervalued assets on the SEHK. In this context, identifying stocks that appear undervalued involves assessing companies with solid fundamentals that are priced below their perceived intrinsic value—an approach that aligns well with current shifts towards more conservative investment strategies in volatile times.

Top 10 Undervalued Stocks Based On Cash Flows In Hong Kong

Name

Current Price

Fair Value (Est)

Discount (Est)

Giant Biogene Holding (SEHK:2367)

HK$39.90

HK$75.98

47.5%

China Resources Mixc Lifestyle Services (SEHK:1209)

HK$23.90

HK$47.68

49.9%

China Cinda Asset Management (SEHK:1359)

HK$0.67

HK$1.29

48.1%

Zijin Mining Group (SEHK:2899)

HK$16.32

HK$32.34

49.5%

West China Cement (SEHK:2233)

HK$1.11

HK$2.15

48.5%

Super Hi International Holding (SEHK:9658)

HK$13.34

HK$25.84

48.4%

BYD (SEHK:1211)

HK$243.00

HK$464.84

47.7%

Mobvista (SEHK:1860)

HK$2.01

HK$3.74

46.3%

Vobile Group (SEHK:3738)

HK$1.24

HK$2.31

46.4%

MicroPort Scientific (SEHK:853)

HK$5.20

HK$9.53

45.4%

Click here to see the full list of 41 stocks from our Undervalued SEHK Stocks Based On Cash Flows screener.

We're going to check out a few of the best picks from our screener tool.

Innovent Biologics

Overview: Innovent Biologics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibodies and other drug assets for oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in China, with a market capitalization of approximately HK$66.03 billion.

Operations: Innovent Biologics generates revenue primarily from its biotechnology segment, totaling CN¥6.21 billion.

Estimated Discount To Fair Value: 34.6%

Innovent Biologics, a key player in the biopharmaceutical space in Hong Kong, appears undervalued based on its cash flows and recent strategic moves. The company's collaboration with IASO Bio enhances its position by divesting rights to FUCASO? while acquiring an 18% stake in IASO Bio, potentially boosting future cash inflows. Despite robust revenue growth forecasts (21.2% per year), Innovent trades at HK$40.55, significantly below the estimated fair value of HK$61.99, suggesting more than 20% undervaluation. Recent clinical advancements and strategic equity investments underscore its potential for improved financial health and market positioning.